Abstract
A large proportion of patients referred for transcatheter tricuspid valve intervention (TTVI) will have the presence of a cardiac implantable electronic device (CIED). In such patients, surgical correction of tricuspid regurgitation (TR) is associated with high rates of morbidity and mortality. Transvenous lead extraction (TLE) could potentially ameliorate CIED-induced TR; however, it carries inherent risks and frequently does not result in TR improvement. As multiple TTVI devices are in trial to gain regulatory approval, understanding which therapy is most appropriate among patients with a CIED is essential. This review centers on the nonsurgical treatment, including TLE and transcatheter tricuspid valve repair and replacement options, aimed at enhancing outcomes in patients with TR who also have concurrent CIEDs.
Original language | English |
---|---|
Pages (from-to) | 790-799 |
Number of pages | 10 |
Journal | Catheterization and Cardiovascular Interventions |
Volume | 104 |
Issue number | 4 |
DOIs | |
State | Published - Oct 1 2024 |
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine
Keywords
- CIED
- pacemaker
- transcatheter tricuspid valve repair
- transcatheter tricuspid valve replacement
- tricuspid regurgitation